SCI Pharmtech, Inc. (TPE: 4119)
Taiwan
· Delayed Price · Currency is TWD 84.80
+0.60 (0.71%)
Jan 20, 2025, 1:30 PM CST
SCI Pharmtech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,413 | 1,204 | 899.74 | 864.22 | 2,689 | 2,356 | Upgrade
|
| Revenue Growth (YoY) | 24.14% | 33.83% | 4.11% | -67.86% | 14.16% | 21.44% | Upgrade
|
| Cost of Revenue | 1,030 | 853.84 | 608.56 | 656.13 | 1,415 | 1,420 | Upgrade
|
| Gross Profit | 383.22 | 350.32 | 291.18 | 208.09 | 1,274 | 935.77 | Upgrade
|
| Selling, General & Admin | 180.47 | 140.93 | 132.56 | 104.08 | 180.56 | 199.73 | Upgrade
|
| Research & Development | 42.82 | 49.09 | 39.65 | 30.35 | 43.37 | 38.92 | Upgrade
|
| Operating Expenses | 223.28 | 190.02 | 172.21 | 134.43 | 222.75 | 238.65 | Upgrade
|
| Operating Income | 159.94 | 160.3 | 118.97 | 73.66 | 1,052 | 697.12 | Upgrade
|
| Interest Expense | -6 | -6.29 | -1.07 | -0.04 | -0.04 | -0.05 | Upgrade
|
| Interest & Investment Income | 9.55 | 6.17 | 6.49 | 10.04 | 12.65 | 4.62 | Upgrade
|
| Earnings From Equity Investments | -19.21 | -13.84 | -12.56 | -13.55 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -2.76 | 2.37 | 27.55 | -15 | -30.63 | -9.97 | Upgrade
|
| Other Non Operating Income (Expenses) | 230.75 | 6.62 | 4.37 | 24.41 | 4.14 | 13.43 | Upgrade
|
| EBT Excluding Unusual Items | 372.27 | 155.33 | 143.75 | 79.52 | 1,038 | 705.15 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.07 | -1.87 | -14.07 | 2.24 | -15.71 | 7.64 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.05 | -0.58 | -1.33 | - | - | -1.62 | Upgrade
|
| Other Unusual Items | - | 0.37 | 101.2 | -16.26 | -1,086 | - | Upgrade
|
| Pretax Income | 584.24 | 364.19 | 387.82 | 65.51 | 455.22 | 711.16 | Upgrade
|
| Income Tax Expense | 100.01 | 69.47 | 79.04 | 9.81 | 95.09 | 140.06 | Upgrade
|
| Net Income | 484.24 | 294.72 | 308.78 | 55.7 | 360.12 | 571.1 | Upgrade
|
| Net Income to Common | 484.24 | 294.72 | 308.78 | 55.7 | 360.12 | 571.1 | Upgrade
|
| Net Income Growth | 28.45% | -4.55% | 454.40% | -84.53% | -36.94% | 27.70% | Upgrade
|
| Shares Outstanding (Basic) | 118 | 109 | 107 | 107 | 107 | 107 | Upgrade
|
| Shares Outstanding (Diluted) | 119 | 110 | 108 | 108 | 108 | 108 | Upgrade
|
| Shares Change (YoY) | 10.21% | 1.87% | 0.08% | -0.49% | -0.26% | -0.07% | Upgrade
|
| EPS (Basic) | 4.09 | 2.70 | 2.88 | 0.52 | 3.36 | 5.32 | Upgrade
|
| EPS (Diluted) | 4.08 | 2.69 | 2.87 | 0.52 | 3.33 | 5.27 | Upgrade
|
| EPS Growth | 16.57% | -6.27% | 456.63% | -84.53% | -36.80% | 27.83% | Upgrade
|
| Free Cash Flow | -696.89 | -813.59 | -871.02 | -490.75 | 753.83 | 592.09 | Upgrade
|
| Free Cash Flow Per Share | -5.87 | -7.42 | -8.10 | -4.56 | 6.98 | 5.47 | Upgrade
|
| Dividend Per Share | 1.250 | 1.250 | 0.222 | - | 0.370 | 4.296 | Upgrade
|
| Dividend Growth | 462.56% | 462.56% | - | - | -91.38% | 38.10% | Upgrade
|
| Gross Margin | 27.11% | 29.09% | 32.36% | 24.08% | 47.39% | 39.72% | Upgrade
|
| Operating Margin | 11.32% | 13.31% | 13.22% | 8.52% | 39.10% | 29.59% | Upgrade
|
| Profit Margin | 34.26% | 24.48% | 34.32% | 6.44% | 13.39% | 24.24% | Upgrade
|
| Free Cash Flow Margin | -49.31% | -67.57% | -96.81% | -56.79% | 28.03% | 25.13% | Upgrade
|
| EBITDA | 374.69 | 303.68 | 207.95 | 135.59 | 1,183 | 831.92 | Upgrade
|
| EBITDA Margin | 26.51% | 25.22% | 23.11% | 15.69% | 43.98% | 35.31% | Upgrade
|
| D&A For EBITDA | 214.76 | 143.38 | 88.98 | 61.93 | 131.25 | 134.8 | Upgrade
|
| EBIT | 159.94 | 160.3 | 118.97 | 73.66 | 1,052 | 697.12 | Upgrade
|
| EBIT Margin | 11.32% | 13.31% | 13.22% | 8.52% | 39.10% | 29.59% | Upgrade
|
| Effective Tax Rate | 17.12% | 19.07% | 20.38% | 14.98% | 20.89% | 19.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.